Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugemalimab Plus Chemotherapy in Real-world Advanced NSCLC
NCT07247227Recruiting
- Sponsor
- Peking Union Medical College
- Start
- Oct 2023
- Primary completion
- May 2027
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Open-label trial of sugemalimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Peking Union Medical College. Primary endpoint: Real-world Progression-Free Survival at 1 year. Started Oct 2023; status: recruiting.
02
Drugs
sugemalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07247227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07247227.